-
Immunomodulation vaccine! FDA grants IO102/IO103 breakthrough drug eligibility: 79% overall remission rate for first-line treatment of melanoma with combined O drug
Time of Update: 2020-12-26
, the company announced that the U.S. Food and Drug Administration (FDA) has granted IO102 and IO103 combined anti-PD-1 monoantial combination therapy to treat non-removable/metastasis melanoma patients with breakthrough drug eligibility (BTD).
-
Endometrial cancer "targeted and immune" treatment! Merca East / Weishi Keytruda and Lenvima Verified Phase 3 study was a great success!
Time of Update: 2020-12-26
Based on data from the latest Phase II trial, the FDA has accelerated the approval of the Keytruda-Lenvima combined treatment in mid-September 2019 for patients with advanced conditions that are not suitable for root-and-treat surgery or radiation therapy, non-MSI-H) or dMMR advanced endometrial cancer.
-
Nature: Cancer cells betray their whereabouts when they evade the immune system
Time of Update: 2020-12-25
, unlike healthy cells, these cancer cells can continue to synthesize proteins to survive, but at a cost: they will be more easily detected by the immune system.
abnormal peptides in melanoma, cancer cells continue to synthesize proteins.
-
J Thromb Haemost: Analysis of thromboembolism risk in patients with ALK and EGFR mutant lung cancer
Time of Update: 2020-12-25
researchers used the Kaplan-Meier method to estimate TE-free and total survival rates in patients with each molecular subtype (wild, ALK and EGFR mutants).
TE is associated with poor survival outcomes in patients with various molecular subsypes of cancer, and these results should be taken into account when making thrombosis prevention decisions.
-
CRISPR-Cas9 technology edited CAR-T cells may enhance the body's potential to fight blood cancer
Time of Update: 2020-12-25
CRISPR technology, which helps scientists lock and edit any unwanted gene, in the case of cancer, can help them better protect against tumors by removing specific genes from T-cells, a method closely linked to CAR-T cell therapy, in which researchers engineer and express new subjects by collecting T-cells from the patient's body itself.
-
First-line immunotherapy for esophageal cancer! Mercedon Keytrud Plus Chemotherapy Program Receives FDA Priority Review: Will Become a New Standard for First-Line Treatment!
Time of Update: 2020-12-25
Currently, Keytruda is approved in the United States, China, and Japan as a single-drug therapy for second-line treatment of patients with relapsed localized late stage or metastatic esophageal squamous cell carcinoma (ESCC) with tumor expression PD-L1 (combined positive score (CPS) ≥10).
-
Turn a "cold tumor" into a "hot tumor"! New CXCR4 antagonist motixafortide to treat pancreatic cancer shows strong results!
Time of Update: 2020-12-25
the team evaluated the efficacy and safety of motixafortide (BL-8040) and the anti-PD-1 therapy Keytruda (Corinthian, generic name: pembrolizumab, paboliju monotherapy) and chemotherapy, as well as the second-line treatment of stage IV pancreatic catheterization (PDAC).
-
Lancet Gastroenterol Hepatol: Preoperative induction chemotherapy for advanced pancreatic cancer Nab-Yew alcohol and Gissytabin need to be followed by FOLFIRINOX?
Time of Update: 2020-12-24
the purpose of this study is to compare the efficacy and safety of Nab-yew alcohol and Nab-yew alcohol-Gissytabin as a multidraught-induced chemotherapy program for localized advanced pancreatic cancer using fluorouracil, folate, olithic acid, and otolium (FOLFIRINOX).
-
China Resources 39 has been granted exclusive license for Oncoceutics' innovative glioma drug ONC201 Greater China
Time of Update: 2020-12-24
ONC201, a core product developed by Oncoceutics, is currently at a critical clinical stage and is a new small molecule with a unique mechanism of action that has proven its anti-cancer activity and safety in a number of clinical trials, including in adult and child patients with high-level gliomas.
-
NAT COMMUN: How does multigene risk affect the probability of breast cancer throughout life?
Time of Update: 2020-12-24
more detail, women with the c.1592delT variant in PALB2 (242 times rich in Finland, 336 carriers) had an average PRS (10-90th percentile) and a lifetime risk of breast cancer of 55 percent (95 percent CI 4 9-61%), however, if the PRS is high, the risk increases to 84% (71-97%), and if the PRS is low ( slt;10th percentile), the risk decreases to 49% (30-68%).
-
Nursing English: Nursing English dialogue in cancer chemotherapy and radiotherapy
Time of Update: 2020-12-24
Yes, the chemo, feeling sick and being hospital away from my family.
Yes, I'm talking about chemotherapy, it's chemotherapy that keeps me sick and vomiting, it's chemotherapy that keeps me trapped in a hospital far from my family.
-
For the first time, the World Health Assembly has pledged to eliminate cervical cancer! Girls should see the HPV vaccine cop dry goods
Time of Update: 2020-12-24
cervical cancer is mostly caused by HPV infection, which is mainly transmitted through direct contact and sexual activity.
, the cervical cancer vaccine was effective for women who had not had sex.
-
FDA approves oral GnRH-affected antagonist Orgovyx for the treatment of advanced prostate cancer
Time of Update: 2020-12-24
the U.S. Food and Drug Administration (FDA) recently said it has approved Myovant Sciences' GnRH-subject antagonist Orgovyx (relugolix) to treat patients with advanced prostate cancer.
approval was supported by the HERO trial, which treated more than 900 patients with androgen-sensitive advanced prostate cancer for at least a year for ongoing androgen deprivation.
-
Tumor vaccine and PD1, melanoma patients with complete remission rate of 45%! Obtained fda breakthrough therapy
Time of Update: 2020-12-24
phase I/II clinical study code-named MM1636 included 30 patients with metastasis melanoma who received the Navuliyu single anti-combined tumor vaccine IO102 and IO103 as first-line treatment.
-
The FDA approved Karyopharm's Xpovio (selinexor) for the treatment of multiple myeloma
Time of Update: 2020-12-24
approval is based on the latest data from the BOSTON III trial, which treated 402 patients with relapsed or incurable multiple myeloma with a 1-3 course of treatment.
results showed that the median PFS was 13.9 months in patients receiving Xpovio combined treatment, compared with 9.5 months in the control group.
-
AstraZeneta's Tagrisso has been approved in the United States as an ancillary therapy for NSCLC
Time of Update: 2020-12-24
Tagrisso has been approved in the United States for first-line treatment of metastasis NSCLC patients with EGFR exon 19 missing or exon 21 L858R mutation, has also been used in second-line treatment to treat metastasis EGFR T790M mutation-positive NSCLC patients.
-
NATURE: How does melanoma respond to tumor immunity?
Time of Update: 2020-12-24
However, in melanoma patients, clinical trials using a combination of inhibiting IDO1 and blocking the PD1 pathline did not improve the effectiveness of treatment compared to individual PD1 path-blocking, suggesting that we did not fully understand the role of IDO1 and the degradation of the resulting tryptophan in mRNA translation and cancer progression.
-
What should families do in the face of their terminally ill relatives? Three suggestions may help you
Time of Update: 2020-12-24
the fluid ascension caused by chest tightness: clinically can be extracted by the way of abdominal water to relieve the patient's feeling of oppression, but after extraction, if there is no corresponding treatment measures, the fluid will continue to produce, so doctors will often leave a catheter for the patient, so that the fluid can be excreted at any time.
-
NATURE: Fat1 gene loss increases tumor dryness and metastasis potential
Time of Update: 2020-12-24
study revealed that in mice and humans with squamous cell carcinoma, the loss of FAT1 function promotes tumor occurrence, progression, invasiveness, dryness and metastasis by inducing mixed EMT states.
-
Cell Death Dis: New ring RNA circXPO1 promotes the development of lung adenocarcinoma
Time of Update: 2020-12-23
previous studies have shown that non-coded RNA (ncRNA) plays a vital role in all types of cancer.
earlier in the study, through RNA sequencing, showed an increase in the expression levels of some circRNAs in LUAD tumor tissue.
